Webinars and Events | May 24, 2023
The latest generation of prescription drugs originally developed to help people manage their type 2 diabetes, such as Ozempic®, have been causing quite a stir for patients, health professionals and benefit plans now that some have been both approved and promoted for treating obesity. The effectiveness of and demand for these newer drugs are prompting some plan sponsors that exclude anti-obesity drugs from coverage to revisit plan rules. However, there are concerns about the potentially large target patient population, as well as the increased utilization and the high cost of these drugs.
This webinar addresses the range of issues plan sponsors face related to weight-loss benefits and potential coverage of newer anti-obesity drug therapies.
Share this page
Don’t have time to watch a video right now? No worries. Here is a copy of the slides from this session.
Download NowHealth, Benefits Administration, Multiemployer Plans, Public Sector, Healthcare Industry, Higher Education, Architecture Engineering & Construction, Pharmaceutical, Corporate
Health, Multiemployer Plans, Public Sector, Healthcare Industry, Higher Education, Corporate, Architecture Engineering & Construction
Health, Multiemployer Plans, Public Sector, Healthcare Industry, Higher Education, Architecture Engineering & Construction, Corporate
This page is for informational purposes only and does not constitute legal, tax or investment advice. You are encouraged to discuss the issues raised here with your legal, tax and other advisors before determining how the issues apply to your specific situations.
© 2024 by The Segal Group, Inc.Terms & Conditions Privacy Policy California Residents Sitemap Disclosure of Compensation Required Notices
We use cookies to collect information about how you use segalco.com.
We use this information to make the website work as well as possible and improve our offering to you.